HDAC3 and acquired polycythemia vera: Although these limitations may reduce the therapeutic window in which a pharmacologic targeting of HDAC3 is beneficial, the strong upregulation in the PV setting harbors the potential to return HDAC3 and (through KLF5) also DSG3 to normal levels.